title: [Cancer of the cheek in a patient under etanercept].
abstract: BACKGROUND
  Etanercept (Enbrel) is a TNF-alpha inhibitor effective in rheumatoid polyarthritis, psoriatic rheumatism, ankylosing spondyloarthritis, chronic plaque psoriasis, and juvenile idiopathic arthritis. Several cases of tumours have been described in patients under etanercept. However, no case of association with oral carcinoma had ever been described. The aim of this study was to report a case of carcinoma of the cheek mucosa in a patient treated with etanercept for rheumatoid polyarthritis.
  
  
  METHODS
  An 82-year-old female patient, non smoker, consulted for a tumour of the oral cavity. History revealed that this lesion had appeared soon after the initiation of etanercept treatment for severe and resistant rheumatoid polyarthritis. Clinical observation revealed a tumour of the right cheek mucosa 5 by 3 cm. The lesion was superficially infiltrative, budding in spots, and verrucous. The clinical observation was otherwise normal. The histological examination of the surgical piece revealed a micro-infiltrative and non-invasive orthoplastic epidermoid carcinoma.
  
  
  CONCLUSIONS
  The possible development of an oral cavity carcinoma should be taken into account when following a patient under TNF-alpha inhibitor treatment. Anti-TNF treatment has improved the management of patients with severe chronic inflammatory diseases. They allow for a better quality of life. Nevertheless, their immunosuppressive effect should be taken into account when prescribed and during follow-up.
authors.affiliation: Service de chirurgie maxillofaciale, centre François-Xavier-Michelet, CHU Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France.
authors.forename: A
authors.initials: A
authors.lastname: Rousseau
authors.forename: R
authors.initials: R
authors.lastname: Taberne
authors.forename: F
authors.initials: F
authors.lastname: Siberchicot
authors.forename: J-C
authors.initials: JC
authors.lastname: Fricain
authors.forename: N
authors.initials: N
authors.lastname: Zwetyenga
mesh_terms: D000368:Aged; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced*; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D009062:Mouth Neoplasms / Q000139:chemically induced*; D018124:Receptors, Tumor Necrosis Factor
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept